Redeye shares its preview of BONESUPPORT’s Q1 2023e results, due April 27.
Redeye will likely increase its forecasts and Fair Value Range of Hanza in an Update following the f...
NeoTX, the partner of Active Biotech developing naptumomab estafenatox, has presented new results fr...
Stänger fas II-studie Guard meddelade i fredags att de valt att avsluta rekryteringen till den påg...
Redeye leaves a note following Faron’s additional study update from the phase I/II BEXMAB study with...
Medivir has presented positive pre-clinical results with fostrox in a triple combination at the AACR...
Sega has announced a recommended cash offer of EUR 9.
Redeye increases its Arise estimates and fair value range following the acquisition of Pohjan Voima.
One-time refinancing and main market expenses to weigh on Q1 Net margin to improve from 0.
Q1e: SEK 190m sales, +4.7% y-o-y; 6.5m EBITA, 3.4% margin Minor estimate changes; reiterate fair val...
Redeye comments on Better Collective’s acquisition of Skycon Limited which expands Better Collective...
Zoomability Int AB meddelade den 14 april att bolagets Zoom Uphill har färdigtestats enligt rullstol...
New contract with Glatfelter OrganoClick announced a new contract with Glatfelter, a global non-wove...
Rekryterar för att fortsätta utveckla erbjudandet och bibehålla tillväxttakten 2022 var ett händelse...
Scanfil’s guidance upgrade arrived early in the year and was of notable size.
Redeye saw a sales performance in the quarter that did not meet our high expectations but still show...
On 13 April, Elanders published preliminary Q1 2023 numbers, suggesting a 16% y/y EBITA uplift and m...
Redeye endorses the announcement that CLS and the US National Institutes of Health Clinical Center h...
Mediasegmentet starkt inför potentiell uppdelning Under kvartalet har GIG konsoliderat förvärvet av ...
Q1 due 4 May; trends continue to look positive... .
